LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Given Imaging Strengthens Position in Gastroesophageal Diagnostic Market

By LabMedica International staff writers
Posted on 13 Apr 2010
Given Imaging Ltd. (Yoqne'am, Israel) completed its acquisition of the privately held diagnostics company, Sierra Scientific Instruments (Los Angeles, CA, USA), for US$35 million in cash. As a result of the purchase, Sierra Scientific has become a wholly owned subsidiary of Given Imaging.

Products developed by Given Imaging use wireless technology and advanced software to enable gastroenterologists visualize diseases of the esophagus, small bowel, and colon. The PillCam capsules are miniature video cameras that patients ingest. Capsule endoscopy provides physicians with natural images of the small intestine via PillCam SB, the esophagus through PillCam ESO, and the colon with PillCam COLON.

Other capsule products developed by Given Imaging include Agile patency capsule, to verify intestinal patency, and Bravo, a wireless, catheter-free, 48-hour pH test, which is used to assess gastroesophageal reflux disease (GERD).

Given Imaging has operating subsidiaries in the United States, Germany, France, Japan, Australia, and Singapore.

Sierra Scientific's products diagnose a range of gastrointestinal disorders, including gastroesophageal reflux disease. The company developed high-resolution manometry through its ManoScan family of products. It also offers a line of reflux monitoring solutions (AccuTrac and Digitrapper), as well as the Polygraf ID stationary gastrointestinal function testing platform.

Related Links:

Given Imaging Ltd.
Sierra Scientific Instruments




Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
Electrolyte Analyzer
BKE-B

Latest Industry News

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
13 Apr 2010  |   Industry

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
13 Apr 2010  |   Industry

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
13 Apr 2010  |   Industry



PURITAN MEDICAL